Abstract
The designer proline-rich antimicrobial peptide A3-APO and its Chex1-Arg20 single chain in vivo metabolite were studied for their ability to induce bacterial resistance upon repeated incubation of Escherichia coli and Klebsiella pneumoniae strains in sublethal concentrations. While no resistant E. coli phenotype emerged to either peptides, after 10 passages the K. pneumoniae strain became resistant to the monomer but not the dimer. The major microbiological difference between A3-APO and Chex1-Arg20 is the improved membrane-disintegrating ability of the dimeric prodrug. Thus, in agreement with earlier studies, the induced resistance likely resides in some membrane component rather than the intracellular target protein DnaK. In support, no genetic alteration in the DnaK multihelical lid region could be observed in any of the sensitive or resistant bacterial strains.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Peptide Research and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
